Results 101 to 110 of about 28,121 (229)

MtGRF8 interacts with MtSymCRK and prevents early bacteroid death during Medicago – Sinorhizobium symbiosis

New Phytologist, Volume 251, Issue 5, Page 2867-2887, September 2026.
MtSymCRK–MtGRF8‐14‐3‐3a, e, h and i functional model in R‐108 nodules. Summary In Medicago littoralis R‐108, Symbiotic CYSTEINE‐RICH RECEPTOR‐LIKE KINASE (MtSymCRK) is required to prevent defense reactions in symbiotic nodules during chronic infection.
Chaoyan Yin, Kévin Magne, Fathi Berrabah, Dario Monachello, Gautier Bernal, Kirankumar S. Mysore, Jiangqi Wen, Catherine Etchebest, Pascal Ratet, Véronique Gruber   +9 more
wiley   +1 more source

Stratification by a polygenic risk score of common variation aids in Alzheimer's disease rare variant discovery

Alzheimer's &Dementia, Volume 22, Issue 8, August 2026.
Abstract INTRODUCTION We utilized an Alzheimer's disease (AD) polygenic risk score (PRS) to discover associations with novel rare variants (RVs). METHODS PRSs for European ancestry (EA) participants of the Alzheimer's Disease Sequencing Project were calculated using summary statistics from a large genome‐wide association study.
Oluwatosin Olayinka, John J. Farrell, Congcong Zhu, Zainab Khurshid, Alzheimer's Disease Sequencing Project, Eden R. Martin, William S. Bush, Margaret A. Pericak‐Vance, Li‐San Wang, Gerard D. Schellenberg, Jonathan L. Haines, Kathryn L. Lunetta, Xiaoling Zhang, Lindsay A. Farrer   +13 more
wiley   +1 more source

Open‐Label, Balanced, Randomized, Single‐Dose, Three‐Treatment, Three‐Sequence, Three‐Period, Three‐Way Crossover Oral Bioequivalence Study of Desmopressin Acetate Oral Solution

Clinical Pharmacology in Drug Development, Volume 15, Issue 8, August 2026.
ABSTRACT Desmopressin is first‐line therapy for central diabetes insipidus, also known as arginine vasopressin deficiency, but presents dosing challenges due to its narrow therapeutic index. This open‐label, randomized, three‐way crossover study evaluated the bioequivalence of a new desmopressin acetate oral solution (50 mcg/mL) compared to ...
Adam Christensen, Axay Parth, Mansi Kotak, Danka Radosavjevic, Catherine Gorman Moore, Byung‐Woun Seo   +5 more
wiley   +1 more source

PharmVar GeneFocus: CYP1A2—Clinical Impact, Genetic Variation, and Updated Nomenclature

Clinical Pharmacology &Therapeutics, Volume 120, Issue 2, Page 313-323, August 2026.
The Pharmacogene Variation Consortium (PharmVar) provides nomenclature for the highly polymorphic human CYP1A2 gene. CYP1A2 plays a crucial role in the biotransformation of several commonly used drugs, including antipsychotics, antidepressants, anxiolytics, and methylxanthines.
Katalin Monostory, Gonzalo Villapalos Garcia, Dora Koller, Solomon Adams, Chad A. Bousman, Evangelia Eirini Tsermpini, Michelle Whirl‐Carrillo, Amy J. Turner, Volker M. Lauschke, Mohamed Nagy, Erin C. Boone, Teri E. Klein, Pablo Zubiaur, Andrea Gaedigk   +13 more
wiley   +1 more source

Discovery of a Potent and Selective MAO‐B Inhibitor From a Donepezil‐Linked Chalcone Library With Promising Antiparkinsonian Activity

Drug Development Research, Volume 87, Issue 5, August 2026.
ABSTRACT A focused library of 19 donepezil‐linked chalcones (DLCs) was efficiently synthesised through microwave‐assisted Claisen‐Schmidt condensation and subsequently profiled for their inhibitory activities against cholinesterases (AChE and BuChE) as well as monoamine oxidases (MAO‐A and MAO‐B).
Azize Kirac‐Aydin, Bishnu Prasad Pandey, Satyajit Mohanty, Rupsa Mondal, Abanish Biswas, Ashok Kumar Pattnaik, Subodh Mondal, Vinay N. Basavanakatti, Nilüfer Bayrak, Venkatesan Jayaprakash, Hoon Kim, Amaç Fatih TuYuN   +11 more
wiley   +1 more source

A New Cytochrome in Liver Microsomes

Journal of Biological Chemistry, 1962
T, OMURA, R, SATO
openaire   +2 more sources

Investigation of the In Vitro and In Vivo Metabolism and μ‐Opioid Receptor Affinity of the Nitazene N‐Pyrrolidino Fluetonitazene

Drug Testing and Analysis, Volume 18, Issue 8, Page 1097-1113, August 2026.
Eight metabolites for N‐pyrrolidino fluetonitazene were identified in vitro, three of which (M2, M6 and M8) were present in an authentic urine sample. M2 was the most abundant in vivo metabolite and is a common marker metabolite of nitazepyne‐type substances.
Severin Zemp, Gaia Alluisetti, Wolfgang Weinmann, Bettina Schrag, Frank Sporkert, Maurine Leclerc, Katharina Elisabeth Grafinger   +6 more
wiley   +1 more source

Phase I Metabolism of Novel Phencyclidine Derivative 3‐Cl‐PCP: In Vitro Studies With Pooled Human Liver Microsomes and Investigation of a Post‐Mortem Case

Drug Testing and Analysis, Volume 18, Issue 8, Page 1036-1053, August 2026.
A fatal 3‐chloro‐phencyclidine (3‐Cl‐PCP) intoxication was investigated by analyzing postmortem samples and a pooled human liver microsomes assay. Tentative metabolite identification was performed by liquid chromatography‐quadrupole time‐of‐flight mass spectrometry (LC‐QTOF‐MS). Seven phase I metabolites were identified.
Johannes Kutzler, Tobias Veit, Thomas Keller, Volker Auwärter   +3 more
wiley   +1 more source

In Vitro Metabolism of Δ8‐, Δ9‐, and Δ10‐THC in Human Hepatocytes: Distinct Δ10‐THC Biotransformation and Implications for Drug Testing

Drug Testing and Analysis, Volume 18, Issue 8, Page 1114-1121, August 2026.
Δ8‐THC and Δ9‐THC showed comparable metabolic profiles. In contrast, Δ10‐THC underwent extensive glucuronidation and hydroxylation, with only minor formation of a carboxy metabolite, indicating a markedly different metabolic pathway. These differences may increase the risk of misidentification and misinterpretation in cannabis drug testing.
Robert Kronstrand, Henrik Green, Markus Loh, Fabian Rüttimann, Manuela Carla Monti   +4 more
wiley   +1 more source

First‐in‐Human Study of a Long‐Acting GLP‐1 Receptor Agonist (TE‐8105) in Overweight or Obese Adults Without Type 2 Diabetes Mellitus

The Journal of Clinical Pharmacology, Volume 66, Issue 8, August 2026.
Abstract Glucagon‐like peptide‐1 (GLP‐1) receptor agonists have revolutionized weight management and are becoming essential for the treatment of obesity‐related medical conditions. This study aimed to determine the pharmacokinetics, preliminary pharmacodynamics, safety, and tolerability of a long‐acting GLP‐1 receptor agonist, TE‐8105, in overweight or
Ya‐Shan Chuang, Jon D. Wright, Mun‐Teng Wong, Kushal J Paneliya, Wei‐Shiung Yang, Hsing‐Mao Chu, Tse Wen Chang, Thomas M Polasek   +7 more
wiley   +1 more source